Page last updated: 2024-12-08
org 30659
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Org 30659: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 159355 |
CHEMBL ID | 2107658 |
SCHEMBL ID | 354145 |
MeSH ID | M0256621 |
Synonyms (26)
Synonym |
---|
tosagestin (usan/inn) |
110072-15-6 |
D06197 |
tosagestin |
(8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-11-methylidene-2,6,7,8,9,10,12,14-octahydro-1h-cyclopenta[a]phenanthren-3-one |
org-30659 |
17-hydroxy-11-methylene-19-nor-17 alpha-pregna-4,15-dien-20-yn-3-one |
19-norpregna-4,15-dien-20-yn-3-one, 17-hydroxy-11-methylene-, (17alpha)- |
11-methylene-delta-15-norethisterone |
org 30659 |
11-methylene-d-15-norethisterone |
19-norpregna-4,15-dien-20-yn-3-one, 17-hydroxy-11-methylene-, (17 alpha)- |
ys7z529o22 , |
17-hydroxy-11-methylene-19-nor-17alpha-pregna-4,15-dien-20-yn-3-one |
unii-ys7z529o22 |
tosagestin [usan:inn] |
CHEMBL2107658 |
letogestin |
SCHEMBL354145 |
tosagestin [inn] |
tosagestin [usan] |
org30659 |
DTXSID50891344 |
(8r,9s,10r,13s,14s,17s)-17-ethynyl-17-hydroxy-13-methyl-11-methylidene-2,6,7,8,9,10,12,14-octahydro-1h-cyclopenta[a]phenanthren-3-one |
Q27294689 |
AKOS040749664 |
Research Excerpts
Pharmacokinetics
The peak concentration and extent of exposure of Org 30659, and to a lesser extent of EE, in Japanese women are higher than in Caucasian women.
Dosage Studied
The area under the curve (AUC) of Org 30659 after single dosing was increased by a factor of 1. The drug can be safely administered orally for 21 days to healthy female volunteers in a dosage of 0.
Excerpt | Relevance | Reference |
---|---|---|
" The dosed radioactivity was predominantly excreted via urine." | ( Excretion balance and metabolism of the progestagen Org 30659 in healthy postmenopausal women. Gloudemans, RH; Groothuis, GM; Rietjens, IM; Verhoeven, CH; Vos, RM, 2000) | 0.56 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (37.50) | 18.2507 |
2000's | 5 (62.50) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.05
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.05) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (12.50%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |